PTO/SB/21 (08-00)

e type a plus sign (+) inside this box -> +

TRANSMITTAL

Approved for use through 10/31/2002. OMB 0651-0031

09/826,609

A --- | E 2004

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

	•	Filing Dat	April 5, 2001	<u> RECEIV</u>	ヒリ
FORM	13 · · · ·	First Nam_d Inventor	ROBERTS, Bruc_L		
(to be used for all correspondence after in	itial filing)	Group Art Unit	1642	OCT 0 9 2	2002
		Examiner Name	Karen A. Canella	TECH CENTER 1	600/290
Total Number of Pages in This Submission	3	Attorney Docket Number	GA0150C		000/1200
	ENCLO	OSURES (check all that apply)			
Fee Transmittal Form	Assignment Papers (for an Application)		After Allowance Communication to Group		
☐ Fee Attached ☐ Drawi		g(s)	Appeal Communication to Board of Appeals and Interferences		
Amendment / Response	Licensing-related Papers		Appeal Communio		
☐ After Final 2 Sheets	Petition		Proprietary Information		
		n to Convert to a onal Application	Status Letter		
		of Attorney, Revocation e of Correspondence Address	Other Enclosure(s		
	Terminal Disclaimer		Return Postca	·	
Express Abandonment Request	Request for Refund				
Information Disclosure Statement	CD, Number of CD(s)				
Certified Copy of Priority Document(s)	Remarks				
Response to Missing Parts/ Incomplete Application					
Response to Missing Parts under 37 CFR 1.52 or 1.53					
SIGNA	TURE OF	APPLICANT, ATTORNEY, C	OR AGENT		
Firm Genzyme Corporati or 15 Pleasant Street Individual name P.O. Box 9322 Framipagham, Mass	Connector	1701 -9 322			
Signature Cly ali		then			
Date /D/1	102				
	CEI	RTIFICATE OF MAILING			
I hereby certify that this correspondence is addressed to: Assistant Commissioner for				nail in an envelope	
Typed or printed name TARYN ANTA		1			
Signature Akyw	W	alek	Date 10-0	01-02-)	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





RECEIVED

OCT 0 9 2002

Patent

TECH CENTER 1600/2900

Our Docket: GA0150C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Roberts et al.

Serial No.: 09/826,609

Filed: April 5, 2001

For: GENES DIFFERENTIALLY EXPRESSED

IN CANCER CELLS TO DESIGN

CANCER VACCINES

Commissioner for Patents Washington, D.C. 20231

Art Unit: 1642

Examiner: Karen A. Canella

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231

notabor 1 2002

Date

Signature of person mailing correspondence

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This communication is being filed in response to the Restriction Requirement mailed September 13, 2002 in connection with the above-identified application.

Accordingly, this response is timely filed.

REMARKS

Claims 1-26 are pending in the subject application and are subject to a restriction requirement.

In the September 13, 2002 Office Action, the Examiner required restriction under 35 U.S.C. § 121 to one of the following allegedly independent and distinct inventions: